EUVIMEDEUVIMED entdecken
Leserbrief

Rituximab Plus Bortezomib for Relapsed and Refractory Warm Autoimmune Hemolytic Anemia: A Prospective Phase 2 Trial

Xijuan Lin, Chen Yang, Junling Zhuang iD, Jian Li iD, Daobin Zhou, Miao Chen iD, Bing Han

American Journal of Hematology · 2025-02 · 100 (2) · 326-329

DOI: 10.1002/ajh.27540 ↗

Kurz gefasst

Leserbrief in der Zeitschrift American Journal of Hematology, online erschienen am 21.12.2024. Verfasst von Xijuan Lin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Peking Union Medical College Hospital and Chinese Academy of Medical Sciences, Beijing, China. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 6 Literaturangaben. Gefördert von: National High Level Hospital Clinical Research Funding, CAMS Innovation Fund for Medical Sciences, National Natural Science Foundation of China.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Department of Hematology, Peking Union Medical College Hospital and Chinese Academy of Medical Sciences, Beijing, China.

ORCID-Profile: Junling Zhuang, Jian Li, Miao Chen

Förderung

  • National High Level Hospital Clinical Research Funding
  • CAMS Innovation Fund for Medical Sciences
  • National Natural Science Foundation of China

Zitieren

APA

Lin, X., Yang, C., Zhuang, J., Li, J., Zhou, D., Chen, M., & Han, B. (2025). Rituximab Plus Bortezomib for Relapsed and Refractory Warm Autoimmune Hemolytic Anemia: A Prospective Phase 2 Trial. American Journal of Hematology, 100(2), 326-329. https://doi.org/10.1002/ajh.27540

Vancouver

Lin X, Yang C, Zhuang J, Li J, Zhou D, Chen M, et al. Rituximab Plus Bortezomib for Relapsed and Refractory Warm Autoimmune Hemolytic Anemia: A Prospective Phase 2 Trial. American Journal of Hematology. 2025;100(2):326-329. doi:10.1002/ajh.27540

BibTeX
@article{Lin2025,
  author = {Lin, Xijuan and Yang, Chen and Zhuang, Junling and Li, Jian and Zhou, Daobin and Chen, Miao and Han, Bing},
  title = {Rituximab Plus Bortezomib for Relapsed and Refractory Warm Autoimmune Hemolytic Anemia: A Prospective Phase 2 Trial},
  journal = {American Journal of Hematology},
  year = {2025},
  volume = {100},
  number = {2},
  pages = {326--329},
  doi = {10.1002/ajh.27540}
}
Kostenlos starten →